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Literature was reviewed to assess the physical aspects governing the present and emerging technologies used in
intraoperative radiation therapy (IORT). Three major technologies were identified: treatment with electrons, treatment
with external generators of kV X-rays and electronic brachytherapy. Although also used in IORT, literature on
brachytherapy with radioactive sources is not systematically reviewed since an extensive own body of specialized
literature and reviews exists in this field. A comparison with radioactive sources is made in the use of balloon
catheters for partial breast irradiation where these are applied in almost an identical applicator technique as used
with kV X-ray sources. The physical constraints of adaption of the dose distribution to the extended target in breast
IORT are compared. Concerning further physical issues, the literature on radiation protection, commissioning,
calibration, quality assurance (QA) and in-vivo dosimetry of the three technologies was reviewed. Several issues
were found in the calibration and the use of dosimetry detectors and phantoms for low energy X-rays which
require further investigation. The uncertainties in the different steps of dose determination were estimated,
leading to an estimated total uncertainty of around 10-15% for IORT procedures. The dose inhomogeneity
caused by the prescription of electrons at 90% and by the steep dose gradient of kV X-rays causes additional
deviations from prescription dose which must be considered in the assessment of dose response in IORT.Background
The duty of physics in radiation therapy is to ensure
therapeutic quality by providing state of the art technical
equipment and procedures, maintaining a safe application
of radiation for patients, personnel and environment and
by minimizing uncertainties in the therapeutic procedures.
Intraoperative radiation therapy (IORT) overcomes many
of the technical difficulties by applying radiation directly
to the surgically opened tumor bed without irradiating
healthy tissue in front of the target. Dose to tissues behind
the target is minimized by applying radiation with ad-
justed penetration such as electrons of appropriate energy
or low energy photons (X-rays). Organs of risk within the
target area can often be mobilized and removed from the
radiation field. Treatment is generally performed with sin-
gle fields of radiation at a fixed distance between source
and target surface which allows minimal treatment plan-
ning and usually consists of calculating monitor units for
the selected energy and a pre-designed applicator which
provides an appropriate dose distribution. Dose distribu-
tions in water are generally documented in an atlas for aCorrespondence: frank.hensley@gmx.de
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Despite this very elementary approach of IORT, a large
number of physical preparations and quality assurance
measures are needed and must be adjusted to the work-
flow of each individual IORT facility. The majority of these
physics issues has been discussed in three reports and
guidelines by the America Association of Physicists in
Medicine (AAPM) [1, 2] and the Italian Istituto Superiore
di Sanità [3], and shall only briefly be enumerated here.
The following article reviews publications on the assess-
ment of physical parameters needed to assure treatment
quality. A special focus is placed on the uncertainties in
these parameters. The review intends to identify issues
that presently remain to be solved and to address path-
ways to their solution, in part also pathways that have not
yet been treated in literature. A number of different
technologies are used for IORT delivery which are often
developed and marketed by a single manufacturer. In
the review, the different devices therefore are often iden-
tified by their brand names in order to characterize the
underlying technology. This naming intends no prefer-
ence or endorsement for any particular commercial
brand and does not imply that a named brand is neces-
sarily superior for the described application.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Interdisciplinary organization and procedures
The basic roles and interactions of the IORT team mem-
bers, including surgeons, radiation oncologists, radiation
physicists, anesthesiologists, nursing staff, pathologist,
and radiation therapist (i.e., the radiotherapy technologist)
have been described in the three IORT reports [1–3]. It is
essential that each member of the interdisciplinary team
knows and respects the responsibilities of the other, often
unfamiliar, co-disciplines. To obtain this interdisciplinary
education, physics must clearly point out regulatory re-
quirements and legal and biological dose limitations as
well as the therapeutic value of physical quality assurance.
The complete team must understand the requirement of
comprehensive commissioning and continuing periodic
controls, the improvements in dose distribution which
can be gained by combined/joint treatment planning
through physicist and radiation oncologist, the need for
continuing research and development and the time and
dose requirements to fulfill all of these procedures.
Some IORT techniques require long irradiation times
so that special anesthetic procedures must be planned,
e.g. remote patient surveillance or in some cases a pro-
tected position at which the anesthesiologist can remain
in the OR during treatment.
Equipment
IORT equipment must fulfil the needs of more disci-
plines than usually considered in radiotherapy. There-
fore, in advance of selection of equipment, the planned
surgical and radiological procedures and set-ups must be
discussed within the complete team. Site visits to oper-
ational IORT facilities and test set-ups e.g. in the show
rooms of the manufacturers or at other sites (or, if
possible, in the planned OR) should be made prior to
equipment selection to detect possible limitations of cer-
tain components. E. g., despite the mobility of modern
IORT accelerators, accelerator positioning for certain
surgical set-ups may not be possible due to interference
of the accelerator stand with the treatment table. The
treatment table itself must be carefully selected in order
to provide sufficient table top motions to allow beam
positioning (in-plane longitudinal and horizontal as well
as tilt motions). Beam set-up for certain irradiations (e.g.
in the abdomen) may require positioning the patient’s
center of mass at large distance from the table column.
Table motions, stability and weight capacity must allow
for the planned techniques. In this context, also
anesthesia access to the patient must be considered and
planned. Modern IORT accelerators generally use beam
stoppers to reduce OR shielding. The position of the
beam stop in relation to the table should be assessed in
advance in order to detect possible interference with
the table which may preclude the planned technique.The table must provide all accessories needed both for
operation and for irradiation. Space around the oper-
ation table must be sufficient for accelerator movement
and docking. The position of the idle accelerator before
and after irradiation must be planned to avoid interfer-
ence with surgical work. Attention must be paid to the
dimensions and weight of the accelerator to ensure that
it can pass through all doors, hallways, elevators etc. on
its way into the OR. The height of the OR must be suit-
able to accommodate the accelerator at the most
extended position needed for treatment. Floor loads of
the OR and all other rooms, hallways and elevators on
the accelerators pathways must be sufficient to carry
the accelerator’s weight. Many of these issues are dis-
cussed in more detail in the IORT guidelines [1–3].
Electron accelerators
The first generation of IORT accelerators were usually
developed in-house on basis of commercial radiotherapy
accelerators, in cooperation with the manufacturers.
Today, such developments are hardly possible due to
medical device regulations. Laborious certifications must
be achieved, and companies are often reluctant to sup-
port in-house developments in order to avoid liabilities.
Therefore the in-house developments have been almost
completely replaced by specialized small mobile IORT
accelerators. At present, three commercial IORT linear
accelerators (linacs) are available on the market. They
are designed as mobile devices in order to be installed
in an existing operation room without the need of re-
constructions for wall mounting. They allow moving
the accelerator to the patient and not vice versa and
can so avoid transport of the surgically opened patient.
They are specially designed for light weight so that
they do not exceed typical floor loads. The designs are
specialized for production of low stray radiation by
avoiding materials with high atomic number that would
cause increased bremsstrahlung. They have straight
beam lines without bending magnets for energy selection
and some have special techniques of beam focusing.
Both measures minimize interactions of defocused elec-
trons with beam line and accelerator structures and thus
bremsstrahlung production. Consequently, the stray X-ray
background produced by the mobile accelerators is con-
siderably smaller than that of conventional radiotherapy
accelerators [4, 5].
The present linacs provide electron beams with ener-
gies between 4 and 12 MeV, depending on type. Beam
energies typically increase in steps of 2MeV or 3 MeV,
equaling an increase in penetration of around 7mm or
1cm per step. Lower penetration or intermediate steps
in penetration can readily be achieved by insertion of
water equivalent bolus between applicator and patient.
Higher energies than 12 MeV are only infrequently
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ination which may cause need for additional shielding.
Neutron production by interactions with heavy elements
begins at electron energies above 8 MeV for Pb or above
10 MeV for Cu and Fe [5]. For the commercial IORT
linacs, measurements by Soriani [4], Loi [6] and Jaradat
and Biggs [7] have shown that the neutron doses pro-
duced by the IORT linacs are considerably smaller than
those for conventional linacs, and that usually no add-
itional shielding for neutrons is needed. Figure 1 shows
the three accelerators presently on the market.
Applicators
The electron beam of an IORT accelerator is collimated
by a fixed conical primary collimator placed immediately
behind the exit window of the accelerator guide. Final
collimation is achieved with a set of cylindrical applica-
tors of various diameters in order to produce different
field sizes. The sterilized applicator is inserted by the
surgeon and radiation oncologist directly into the surgi-
cal opening above the target in a position and entrance
angle which directs the beam through the underlying
target tissues. Alignment of the applicator with the beam
is adjusted by moving the accelerator to the correct
position and angle, providing an unchanged position of
the applicator. This is achieved by two techniques: with
hard docking the applicator is mechanically locked onto
the accelerator head. This means one must move the
accelerator over the end of the applicator and carefully
attach the applicator end to a receptor on the head
(Fig. 2a) without moving the applicator. With the soft
docking technique (Fig. 2b, c) the applicator is rigidly
attached to the table with a stand and clamp. The accel-
erator is also moved over the applicator end but not
mechanically attached. Alignment is achieved at distance
by a laser guidance system which indicates the correctFig. 1 Mobile electron accelerators for intraoperative radiation therapy. a Th
CA 94085, USA), b the Liac, c the Novac 7 (both: Sit Sordina IORT Technologicentering, angle and distance of applicator and acceler-
ator. The principle of soft docking systems is explained
in detail in references [2, 8] and [9]. Advantages of this
system are the lower risk of injury of the patient by
forces from the moving accelerator or electrical contact
to the machine. The applicator is fixed in its position so
that no misalignment from its intended entrance angle
by movement during the docking process can occur.
The soft docking system uses thin-walled metallic appli-
cators while the hard docking machines have transparent
plastic applicators allowing a direct view of the target
during the docking procedure. A disadvantage of the
plastic applicators can be their thicker walls which re-
quire a larger surgical opening, a disadvantage of hard
docking can be longer time for machine alignment.
Depending on the planned treatment sites one may
encounter limitations in applicator size and design.
Standard (round) applicators are usually provided by the
manufacturers in a range between 3-4cm up to 10cm
diameter in steps of 1cm or, by some manufacturers,
0.5cm. One manufacturer (Intraop) provides elongated
applicators with field sizes of 7×12 cm2, 8×15 cm2 and
8×20 cm2, which use an additional flattening filter which
reduces the output by approximately a factor of two and
reduces the beam penetration (R90) by about 2mm. A
prototype of these applicators is described by Janssen
et al. [10]. Larger field sizes can be achieved by using ap-
plicators with a beveled end, however one must be aware
that the dose distribution of such an applicator is asym-
metrical, extends into tissue beyond the applicator tip at
an angle and has less penetration in depth under the
beam entrance surface than the comparable straight
applicator. Abutting fields is possible with applicators
providing one straight side or by producing a straight
field edge with an absorber under the applicator en-
trance [11, 12]. Characteristics of dose distributions frome Mobetron (IntraOp Medical Corporation, 570 Del Rey Ave, Sunnyvale,
es Spa, Galleria del Pozzo Rosso, 13, 36100 Vicenza VI, Italy)
Fig. 2 Hard and soft docking technique in electron IORT. a Hard docking: the applicator is attached to a receptor on the accelerator head by a
sterile person while a second sterile person holds the applicator in place. (shown for a Liac accelerator). b Soft docking: the applicator is attached
to the couch with a table stand. There is no mechanical connection between applicator and accelerator. (shown for a Mobetron accelerator).
c The alignment of accelerator and applicator is adjusted with a laser alignment system. (Shown for a Siemens Mevatron ME accelerator)
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shaping by straight lead absorbers are described by
Esposito et al. [13] and further discussed in the section
on commissioning in electron IORT. Applicators with
one straight side for field matching (“Squircle applica-
tors”) have been published for older machines, but are
not regularly provided by the manufacturers [14].The
development of a beam shaper producing rectangular
and squircle fields of adjustable size is reported for one
of the mobile accelerators [15]. The applicator ends at a
distance above the patient surface. Soriani et al. describe
the changes in electron depth dose behavior and output
factors connected to both field shaping and the distance
of the applicator from the patient surface [15]. The cor-
rect alignment of this device is not clear. The authors
propose a light field which so far has not been described
in publication. It must be recognized that any method of
field matching requires an examination of the correct
gap width between the abutted fields in order to avoid
hot or cold spots at the intersection.
Attention must be payed to applicator sterilization
workflow so that the required applicator is always
available at the time of operation and applicators are
not damaged during sterilization. Sterilization of the
applicators must be planned together with nursing
staff. The number of applicators should allow for dou-
bles of those applicator sizes which are probable to be
used twice in one day.IORT irradiators using kV X-rays
External kilovoltage X-ray generators
Several devices are available for IORT applying low en-
ergy X-rays. The most frequently used device is the
Intrabeam System (Carl Zeiss Meditec AG, Göschwitzer
Str. 51-52, 07745 Jena, Germany, Fig. 3a) , a miniature
50 kV X-ray generator which accelerates a beam of elec-
trons beam from an electron gun down a thin (3.2 mm
diameter) drift tube (Fig. 3b) at the end of which it hits a
thin hemispherical gold target. The target sits inside a
hemispherical Be beam-exit window which is covered by
a thin film of titanium nitride for biocompatibility. An
isotropic distribution of bremsstrahlung is produced by
oscillating (“dithering”) the beam around the tube axis
in a circular movement with a set of deflector coils.
Detailed descriptions of a precursor type of generator,
the Photon Radiosurgery System (PRS) (Photoelectron
Corporation, Waltham, MA 02154, USA) are given by
Dinsmore et al. [16] and Beatty et al. [17]. This system
was purchased by Zeiss and with some improvements
(which do not change the physical properties of the gen-
erated X-Rays) is now the core technology used in the
Intrabeam. Many features of the present system are
described by Armoogum et al. [18] and Eaton [19]. The
device was first introduced for the irradiation of brain
tumors [20]. Using the spherical plastic applicators
shown in Fig. 3d it is today mainly used for intraopera-
tive breast irradiation within accelerated partial breast
Fig. 3 The Zeiss Intrabeam System (Carl Zeiss Meditec AG, Göschwitzer Str. 51-52, 07745 Jena, Germany). a The X-ray source (XRS) with a spherical
breast applicator mounted on the floor stand. b The XRS. c Schematic drawing of the XRS accelerator. d Spherical applicators for breast IORT
Hensley Radiation Oncology  (2017) 12:37 Page 5 of 30treatment (APBI) [21–23] and also advanced boost treat-
ment [24]. With surface applicators [25], flat intraopera-
tive targets can be treated. Special metallic sleeves to
guide the drift tube allow intraoperative irradiation during
kyphoplastic stabilization of vertebral metastases (Kypho-
IORT) [26, 27]. A similar technique of partial breast IORT
is possible with the Papillon system (Ariane Medical Sys-
tems Limited, Derby DE1 3BY UK ), which uses a switch-
able 30/50 kV X-ray generator and a Chaoul-type (hollow)
rod anode tube covered by spherical applicators (Fig. 4). A
technical description of the X-ray tube is given by Croce
et al [28]. An advantage of this system is its higher dose
rate of around 10Gy/min for most applications [29] which
allows shorter treatment times than the 30-50min for
20Gy in breast treatments with the Intrabeam.
A further class of irradiation techniques in intra and
perioperative radiotherapy uses the Xoft Axxent mini-
ature X-ray tube or conventional radioactive afterloading
sources. Although radiation is often applied in several
postoperative fractions, the surgical procedures concern-
ing target preparation and also the radiotherapy issues of
target coverage are comparable to IORT. Especially accel-
erated radiotherapy of breast cancer with intraoperatively
placed balloon catheters is often considered as alternative
to IOERT. Other techniques using intraoperative flaps
and also intraoperatively placed catheters for later irradi-
ation will not be discussed.The Xoft Axxent miniature X-ray source (“electronic
brachytherapy”)
Due to its small dimensions (15mm length × 2.25mm
diameter) the Xoft Axxent source (Xoft Inc. 345 Potero
Ave. Sunnyvale, CA 94085, USA, Fig. 5a) can be posi-
tioned inside an applicator via a flexible 5.4 mm diam-
eter water-cooling catheter (Fig. 5b). It is used for
breast IORT together with a balloon catheter (Fig. 5c).
A detailed description of the device and its application
is given by Park et al. [30]. Dosimetry parameters for
the Xoft Axxent source for dose calculation with the
AAPM TG43 formalism [31] are given by Rivard et al.
[32] for three voltage settings 40kV, 45kv and 50kV.
Originally, the source needed to be replaced after 10
applications (or 170 min of irradiation time) requiring
new calibration and quality assurance [30]. Meanwhile
the manufacturer’s user manual manufacturer states
that 750 min of irradiation time are possible.
The present technology used in kV-IORT is described
in a review on electronic brachytherapy by Eaton [33].
Although most of the devices described there are intended
for contact brachytherapy, many can also be used for
intraoperative irradiation.
The major advantage of kV-IORT is its need for sig-
nificantly less radiation protection in comparison to high
energy accelerators (discussed below). Disadvantages are
the steep dose decrease leading to a coverage of only
Fig. 4 The Papillon system (Ariane Medical Systems Limited, Derby DE1 3BY UK). a The X-ray source mounted on the floor stand. b Spherical
applicators for breast IORT
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in the section IORT targets, target preparation, dose cover-
age) together with deeper penetration of radiation and
higher doses to tissues beyond the target.
Radioactive afterloading sources
The literature on radioactive afterloading sources is not
systematically reviewed in this work, however certain
aspects are compared since the balloon technique for
breast IORT with electronic and radioactive sources is
almost identical. Due to the higher photon energies of
the afterloading sources (Ir-192 : mean energy 380 keV),
conventional afterloading has a slightly flatter dose gra-
dient than kV X-rays (the dose gradient with both mo-
dalities is dominated by the inverse square law) but on
the other hand requires shielding of the treatment room.
Shielding the OR can be avoided by a perioperative ap-
proach in which the applicator is placed during surgery,
but irradiation takes place at a later time in a shielded
brachytherapy vault. For breast treatment with Ir-192
sources, a number of balloon applicators with multiple
source guiding catheters (struts) are available which canproduce a better target coverage with dose but can also
produce higher skin doses. (see paragraph IORT targets,
target preparation, dose coverage). Different types of
balloon applicators are described in a review of APBI
techniques by Njeh et al. [34].
IORT targets, target preparation, dose coverage
Originally the typical target of IORT was the surgical
margin in which tumor cells remain due to incomplete
resection or microscopic infiltration. The target was
therefore usually a superficial thin layer of tissue which
can be covered with sufficiently homogeneous dose by
low energy electrons or photons. The use of IORT in
APBI and boost irradiation within breast conserving
treatment of breast cancer has changed this paradigm.
The pathological study of Holland et al. showed that in
43% of patients with invasive cancers which are eligible
for breast conserving treatment tumor additional tumor
foci were found beyond a radius of 2cm surrounding the
tumor, the number decreasing to 17% at 3cm and 10%
at 4cm [35]. A margin of 1-2 cm of tissue surrounding
the original tumor bed is therefore usually taken as
Fig. 5 The Xoft Axxent System (Xoft Inc. 345 Potero Ave. Sunnyvale, CA 94085, USA). a Schematic diagram of the X-ray source. b Left: the cooling
tube in which the source is guided to the irradiation position. Right top: The source, bottom: light emission during source operation. c Spherical
balloon applicators for breast IORT
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fines an extended volume of several cm3 which must be
prepared for irradiation and covered with the prescrip-
tion dose. Treating the larger target volume can require
higher electron energies or techniques with kV X-rays
which both can cause more dose in tissues surround-
ing the target and in some cases require additional pro-
tection of risk tissues.
IORT with electrons
In IORT with electrons the lateral (side) walls of the
excision cavity must be mobilized and drawn together to
form a compact target volume which can be completely
covered by the applicator. Such a volume will be a few
cm thick, so that typically an electron energy is chosen
which deposits 90% of the central axis maximum dose
at the deep side of the target. Prescription dose is
defined at this position so that in effect, a maximum
overdose of 11% is accepted in the target [36, 37].Additionally, since the dose profiles of electron beams
are only flat in the central region, the applicator must
be selected approximately 2cm larger than the target
diameter in order to cover the volume with the refer-
ence dose [37]. Many institutions following the original
ELIOT protocol protect risk tissues behind the target
(ribs, lung, heart) by inserting a shielding plate between
the mobilized target and the pectoralis muscle [38, 39].
The shields typically consist of a metal absorber (Pb,
CU) covered with a layer of low Z material (Al, PTFE)
to absorb backscattered electrons [40, 41]. Possibly, the
backscatter can be considered as a desired increase of
target dose.
kV-IORT
With the spherical applicators and balloons used with
kV X-rays and Ir-192, target preparation must ensure a
close adherence of the surgical cavity to the applicator
surface. Tissues at distance will receive significantly
Fig. 6 Maximum, mean and minimum doses in 10 mm thick spherical
shells of tissue surrounding Intrabeam breast applicators for different
depths of prescription of the reference dose with different sizes of
applicators. a prescription at the applicator surface. b prescription at
10mm distance from the applicator surface. c prescription at 20mm
distance from the applicator surface. The prescription dose is defined
as unity for the minimum target dose with the 30mm applicator in
each diagram. For small applicators, a prescription at the applicator
surface (a) produces smaller overdoses at the applicator surface,
however also lower doses at a depth of 10mm which is considered
as the margin surrounding the tumor cavity which must be treated.
Prescription at 10mm depth ensures that the desired dose arrives
at this depth, produces higher overdoses for small applicators,
prescription at 20mm depth increases the overdoses. Therefore the
authors conclude that a prescription at 10mm depth is the best
compromise in order to ensure that desired dose arrives at depth
for all applicator sizes. From Ebert and Carruthers (2003) [35]
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must be retracted from the entrance of the applicator to
minimize skin dose [21]. With the spherical applicators
used with the Intrabeam and Papillon system, dose is
usually prescribed at the applicator surface and (largely due
to inverse square of distance) decreases to around 28-37%
at 10mm distance from the surface, depending on applica-
tor size, and to 11-20% at 20mm distance [42–44].
Skin dose can be a concern when the applicator is close
to the surface although a question to be resolved is what
the desired maximum dose should be [21]. With these
applicators, the typical prescription dose is twice the
dose given with electrons resulting in around 46-80% of
typical electron doses at 1cm and 22-40% at 2cm depth.
Ebert and Carruthers [42] use Monte Carlo simulations
to calculate dose-volume histograms (DVHs) for these
heterogeneous dose distributions in a target shell of
10mm thickness surrounding different applicator sizes
which is considered as the volume needing treatment.
From these DVHs, the relation of maximum (surface),
mean and minimum dose is calculated for three different
methods of dose prescription at either the applicator
surface or at 10mm and 20mm target depth (shown in
Fig. 6), and compared for different applicator diameters.
The comparison shows that the least variation in over-
dose in the target is achieved with prescription at the
surface of different applicator sizes, however at cost of
the mean and minimum doses (Fig. 6a). The authors
conclude that dose prescription at 10mm depth is prob-
ably the best compromise in order to ensure the desired
dose at this depth for all sizes of applicators (Fig. 6b).
(Note that the Targit trial recommends dose prescrip-
tion at the applicator surface [21, 22].) The calculations
show that the dose decrease of low energy X-rays in
breast tissue is steeper than in water. This can lead to
an underdose of 3-5% if calculated in water. They also
show the higher doses to bone (around a factor 3 for
the first mm of bone tissue) and the dose reduction due
to missing backscatter when the target is near the skin.
Dose reductions can range between 25-40% for tissues
at 1 cm from skin and 0-10% for tissues at 5 cm from
the skin. The larger reduction at both tissue-skin dis-
tances holds for an applicator-skin distance of 10mm,
the smaller for a distance of 5cm Fig. 7). Breast treat-
ments are usually performed covering the patient sur-
face over the applicator with a lead-rubber protection
sheet similar to those provided by Zeiss (0.25mm Pb
equivalent). Using the Ebert and Carruthers data [42]
one can estimate that the backscatter from the shield-
ing sheet will compensate for some of the reduction of
surface dose. On the other hand backscatter will in-
crease skin dose, however to a smaller amount since
the retracted skin should typically lie at more than 3-5
cm distance from the applicator.
Fig. 7 Dose reduction due to missing backscatter at different depths under the tissue surface for three different depths of the applicator surface
in tissue (10mm, 30mm and 50mm) for a 30mm diameter intrabeam applicator. For shallow depths of the applicator dose reduction in superficial
tissues can amount as much as 25-40%. From Ebert and Carruthers (2003) [35]
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the dose distribution can be improved by loading multiple
source positions and generating a computer-optimized
treatment plan. Dose distribution can be evaluated with
dose-volume histogram-based dose metrics. With radio-
active sources, multi-channel (multi-strut) applicators can
be used to treat asymmetrical targets. A study comparing
Ir-192 dose distributions for single lumen and multi-strut
balloons with different dose calculation algorithms shows
that dose coverage of a spherical shell of target depends
more on the choice of optimization algorithm than on the
number of source channels. Using inverse optimization
with simulated annealing (IPSA), a D90 metric (dose to
90% of the target volume) of 99.95% vs. 102.56% of
prescription dose is achieved for multi-strut vs. single
lumen applicators [45]. With a simpler dose point based
optimization D90 metrics of 88.4% vs. 90.27% are
achieved. With the Xoft Axxent source and a single
lumen applicator similar dose coverage (D90 = 101.2-
103.9%) is calculated when assuming a homogenous
water phantom [46]. For the low energy X-rays of the
Xoft Axxent system this study calculates a reduction of
D90 = 103.9% in homogeneous water vs. D90 = 98.9% cal-
culated in a more realistic heterogeneous phantom. As a
desirable effect, the heterogeneous calculations show a
larger reduction D0.2cc (maximum dose to 0.2cm
3 of tis-
sue) for skin dose from 92.9% (water) to 81.4% (hetero-
geneous) due to missing backscatter. A similar reduction
should apply with Ir-192 where Skowronek et al. [45]
find skin doses (Dmax) of 81.34-85.83% of prescription
dose when calculated in water. This is confirmed by
measurements of skin dose by Sadeghi et al. [47] who
find average skin doses of 78.5% (range 56-488cGy, aver-
age 267cGy for a prescription dose of 340cGy) depending
on tumor depth and size of applicator.Radiation protection
Electron accelerators
An essential consideration in selecting and planning an
IORT facility is the required radiation protection. Manu-
facturers of mobile IORT accelerators claim that their
devices can be operated in an unshielded OR for limited
numbers of around 3-5 patients per week. In reality,
most ORs need some additional radiation protection. At
minimum, safety devices like warning signals and trans-
parencies, door interlocks and emergency stops are
required. The manufacturers usually provide diagrams of
stray radiation which can also be found in publications
(Novac 7: [48], Liac: [4, 49], Mobetron: [50, 51]). Typical
stray doses at 1m distance from the patient are similar
for the commercial machines (since they are mainly
caused by the bremsstrahlung produced in the patient
(or phantom) as can be seen in the diagrams in [4] and
[51]) and around 6μSv per Gy of patient dose [4, 51]. It
is often difficult to pre-calculate the radiation levels in
surrounding areas due to missing information on wall
construction and the large range of possible machine po-
sitions and beam directions. Since the commercial ma-
chines are mobile, it is a reasonable consideration to ask
the provider to perform test measurements with a test
machine in advance of purchase and final calculation of
shielding requirements. Regulatory bodies are usually
prepared to grant test licenses which allow irradiation
under additional safety precautions such as testing at
times of low occupancy and blocking admission to sur-
rounding areas. When preparing a radiation plan one
must consider that the highest levels of stray radiation
usually occur in the beam direction, immediately adja-
cent to the beam stop. Therefore, critical areas are often
the rooms below the IORT OR. Radiation safety regula-
tions usually require shielding which reduces ambient
Hensley Radiation Oncology  (2017) 12:37 Page 10 of 30dose below the permitted levels at any occupied position
around the OR under the assumption that the highest
possible rate of stray radiation occurs in this direction
during the complete workload. Radiation protection
regulations generally allow use factors with which the
workload in a certain direction can be reduced according
to the fraction of time in which treatment beam is
directed towards a particular barrier (e.g. NCRP 49 [52]
below), however the constraints are different in different
countries. E.g., German standards (DIN 6847-2 [53])
allow only a factor of either 1.0 or of 0.1, when use is
less than 10% of the workload. In many situations, due
to the variability of machine position and beam angle,
agreement on the use factor is difficult to achieve
between user and licensing authority, leading to the
requirement of additional structural shielding in direc-
tions which in effect see only a fraction of the workload.
The need for structural shielding could in principle be
reduced by the use of mobile shielding walls as they are
suggested by some manufacturers. Substituting structral
by mobile shielding is frequently not permitted by licens-
ing authorities due to the lack of control of correct place-
ment when this is totally subject to the responsibility of
the personnel. A possibility may be the development of
interlocked systems which only permit irradiation if the
crucial directions around the accelerator are protected by
correctly positioned mobile shields.
The workload in the radiation plan must include suffi-
cient dose to perform irradiations for quality assurance
(QA), maintenance and repairs. An alternative can be a
separate shielded vault where these tasks are performed.
However such an installation will itself cause extra costs
for space and radiation protection. Frequent transporta-
tion of the accelerator consumes time and manpower
and typically will require shutting down the machine
after QA and re-starting it in the OR which may change
its operating conditions. More considerations for radi-
ation protection are discussed in the reports of AAPM
TG72 and the Italian Guideline [2, 3].
In radiation surveys it must be recognized that the
IORT accelerators produce pulsed radiation. Some sur-
vey meters show incorrect readings in pulsed radiation in
which the instantaneous dose rate in the pulse can exceed
the instrument’s linear range [54]. Especially for measure-
ments inside the treatment room, measurements of ambi-
ent radiation should preferably be performed with pulse-
insensitive devices such as TLDs or with ionization cham-
bers, which however can show the recombination losses
discussed in the section on dosimetry.
X-ray devices
A key reason for the use of kV X-rays in IORT is their
lower requirement of radiation protection. As a first
guess one would assume that a kV-IORT device needsroughly the same amount of radiation protection as a C-
arm fluoroscopy unit as often used in the OR. Schneider
et al. [55] confirm this assumption by measuring the
dose rate surrounding the Intrabeam system and a C-
arm unit in phantom arrangements simulating kypho-
plastic radiotherapy, an intraoperative a breast treatment
and a fluoroscopic procedure. For the C-arm they find
dose rates of 12.7 mSv/h at the phantom surface and 56
μSv/h at 2m distance from the phantom. For Kypho-
IORT the dose rates are 63.6 mSv/h (phantom surface)
and 66μSv/h (2m), and for breast IORT 28.2 mSv/h
(phantom surface) and 27μSv/h (2m). They estimate a
workload of 260 treatments per year (1 patient per day, 5
days per week, 52 weeks) with 6 minutes per treatment
for Kypho-IORT, 30 minutes per treatment for breast and
in comparison 15 minutes C-arm use per day. With these
numbers they compare the radius of the area around the
patient/irradiator which receives more than 6 mSv per
year and therefore defines a controlled area. They find a
radius of 5.8 m for the C-arm, 6.7 m for Kypho-IORT and
3.4 m for breast IORT. For the breast simulations the
phantom surface was covered by lead-rubber shielding
equivalent to 0.175 mm of Pb which the authors state
should reduce dose transmission to < 0.5%. Without such
shielding, the controlled area and also the need for other
shielding measures would be larger. Eaton et al. [56] re-
port an ambient dose equivalent rate of 10.3 mSvh-1 at 1
m distance from the 3 cm applicator of an Intrabeam sys-
tem placed on polystyrene blocks (to reduce scatter). With
this set-up and with both a collimated and an attenuated
beam they measure transmission factors for several shield-
ing materials (tungsten-rubber sheets, lead, plasterboard,
dry brick). They find that reference transmission factors
for an X-rax unit at 50 kVp with 2mm Al filtration [57]
are applicable (within a factor 2) for the treatment situ-
ation when the applicator is covered by patient and a sheet
of tungsten rubber. The reference factors underestimate
the transmission for an unattenuated and collimated
beam. The report also includes measurements around a
phantom set-up in which the applicator was either un-
shielded or inserted into wax bolus and covered by a sheet
of tungsten rubber and also an environmental survey dur-
ing 40 patient treatments. From the results the authors
conclude that involved personnel (system operator and
anesthesiologist) may stay in the treatment room with ap-
propriate protection, other personnel must leave the OR.
This decision is mainly to facilitate administration and
to minimize training needs. As radiation protection in
the OR, the institution uses mobile lead screens al-
though also a lead apron would provide sufficient
shielding. The patient treatment survey shows that due
to varying positions of patient, treatment unit, lead
screens etc., instantaneous dose rates can occasionally
be higher than found in an initial survey. The authors
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areas must be declared in a conservative way. One must
expect that also for kV X-ray devices the licensing author-
ities will often be reluctant to permitting mobile lead
shields and allowing personnel to remain in the OR during
treatment. However one can argue that - in contrast to
the use of a C-arm fluoroscopy unit in the OR – IORT is
an extremely extraordinary situation during a limited and
well-announced time period involving highly trained
personnel under surveillance or even in presence of a
medical physicist. This may justify that personnel can re-
main in the OR during treatment if sufficient protection is
provided, however agreement with licensing authorities
must be achieved in every individual case. In any case,
also kV IORT devices require safety installations like
warning signals and transparencies, emergency stops,
and if possible, door interlocks.
Commissioning, dosimetry, quality assurance
Commissioning mobile electron accelerators
After acceptance testing, commissioning of an IORT
device requires the measurement of all machine specific
data needed for future treatment. For mobile electron
accelerators, the report of AAPM TG 72 [2] gives a list
of Items to be measured during commissioning includ-
ing depth dose distributions and beam profiles at several
depths, output factors for every used beam energy and
applicator, leakage profiles at various depths outside
selected applicators, air gap factors, and beam output
calibration for every energy. These measurements re-
quire high doses and a large amount of time for which
both staff and a measuring vault with sufficient radiation
protection must be available and planned in advance.
For the commissioning of an accelerator with 6 energies
and 16 applicators, Hensley reports a dose consumption
of 5145 Gy [58]. For modern mobile accelerators with
around 40 applicators and 3 to 4 energies this would
extrapolate to 6000-7000 Gy. A considerable reduction
of time and dose could be achieved if the use of an atlas
of pre-determined dose distributions were permitted
which would only need to be verified for a smaller set of
applicators. Such an atlas could be provided by the man-
ufacturers or a task group authorized by medical physics
societies similar to the practice in brachytherapy. It
would require updates for machine changes and the
obligation that manufacturers report relevant changes.
Measured data could be cross-checked with Monte
Carlo simulations. Such simulations exist for several mo-
bile IORT accelerators for various purposes [10, 59–61]
and could be further developed to predict and verify
measured data sets. Commissioning especially of small
and beveled applicators and measurement of output
factors should preferentially be performed with small de-
tectors which integrate only a small portion of the non-flat dose profiles. Electron diodes can be used after test of
their performance in the pulsed beams. They should be
frequently re-calibrated since their sensitivity may change
with the high doses applied with IORT accelerators.
Commissioning of beveled applicators is difficult and
must be performed with great care since the correct pos-
ition of the clinical axis (the intersection of the inclined
central beam axis and the patient surface) is not easily
found with the usual measuring tools. Correct position of
the clinical axis (or some other reproducible point under
the applicator) is essential in order to determine reprodu-
cible output factors for beveled cones. The mobile acceler-
ators have no positioning aids such as light fields or
alignment lasers. Beam centering tools to find the central
beam axis provided by water phantom software cannot be
used due to the asymmetric dose profiles. A positioning
tool described by Runz et al. [62] uses templates mounted
on the chamber drive of a water phantom to align the ap-
plicator end with the water surface and define the position
of the detector in relation to the central beam axis which
at the water surface coincides with the clinical axis.
Dosimetry of IORT systems
Electron dosimetry
Reference dosimetry for electrons is performed following
the international dosimetry protocol IAEA TRS 398 [63],
or national protocols such as AAPM TG 51 [64] in the
United States or DIN 6800-2 [65] in Germany. These
protocols recommend calibration of electron beams
under standardized conditions with either plane- parallel
ionization chambers (or, for higher energies than usually
provided with mobile accelerators with thimble chambers).
Calibration is recommended for a standard rectangular
field of 10×10cm2 (or for higher energies at 20×20cm2)
which is not available with the mobile accelerators. The
protocols provide energy correction factors kQ for the
ionization chamber at a reference depth zref which is
determined from the 50% depth R50 on the central axis
of the standard field. The depth R50 is used as parameter
to determine the mean electron energy of the beam at
the phantom surface. This energy determination is valid
only under reference conditions and for broad beam
geometry i.e. for fields large enough that depth dose no
longer varies with field size. As shown in the report
IAEA TRS 381 [66] the water/air ratios of electron stop-
ping powers at zref which determine the beam quality
correction factor (TG51: kQ , TRS398: kQ,0 , DIN 6800-
2: kE,R ) depend on the beam energy but do not strongly
depend on field size. Calibration of IORT accelerators
should therefore be performed for the largest applicator
and constancy of the depth dose distributions at this
field size should be confirmed. Although the closed-wall
applicators used in IORT will probably produce more
scattered radiation than the applicators on conventional
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beam geometry, one can assume that that the errors in
the beam quality correction factor for the large applica-
tors will be small. For beams of the Novac7 and the Liac
with energies between 5 MeV and 10 MeV, Righi et al.
[60] show that at zref the differences between Monte
Carlo calculated (water/air) stopping power ratios and
the values given in IAEA TRS 398 [63] are smaller than
0.4%, but increase at larger depths.
Dosimetry of pulsed electron beams
All the mobile linear IORT accelerators on the market
produce high dose rates (around 10 Gy/min) at low
pulse repetition frequencies between 9 and 40Hz and
therefore produce large doses per pulse ranging between
3 and 60 mGy. For large pulse doses IAEA TRS 398 [63]
and AAPM TG 51 [64] recommend correction for
recombination losses of ionization chambers by the
Two Voltage Analysis (TVA) method based on Boag’s
theory [67–70]. This method overestimates recombin-
ation losses due to negligence of the free electrons in
the gas filling of an ionization chamber (IC). For a
Novac 7 accelerator with pulse doses between 30 and
60 mGy/pulse, Piermattei et al. report an overesti-
mation of the correction factor kS with the TVA
method by of up to 20% [71] and suggest the determin-
ation of kS by comparison of dose measurements with
ionization chambers and calibrated radiochromic films.
Improved calculation models for kS were published by
Di Martino et al. [72] and Laitano et al. [73].
Cella et al. [74] compare the predictions of the Di
Matino model and three alternative models suggested
by Laitano by comparison of measurements with two
plane-parallel ionization chambers (Markus and Ad-
vanced Markus, PTW Freiburg) with a second set of
measurements with pulse-independent ferrous sulfate
(Fricke) dosimeters in beams of a Novac 7 accelerator
(for pulse doses between 21.4 and 69.8mGy, measured
with Fricke dosimeters). They find that the validity of
the recombination corrections calculated by the different
models depends on chamber type and factors such as
chamber voltage.
Ghorbanpour et al. [75] compare the recombination
correction kS for a plane-parallel ionization chamber
(Advanced Markus chamber, electrode spacing 1mm,
PTW Freiburg, Germany) as calculated by TVA and by
3 alternative models from Laitano. They obtain kS with
an uncertainty of 2.1% by comparing dose measurements
with calibrated radiochromic film with those of an un-
corrected ionization chamber. For the pulsed beam of a
Novac 7 (2.8 – 43mGy/pulse) they find deviations <3%
for all three Laitano models, which agree among each
other within 1%. For the TVA method they find larger
deviations up to 4.2%. A comparison with kS valuesdetermined with a Jaffe plot (described in IAEA TRS 398
[63], AAPM TG 51 [64], and DIN 6800-2 [65]) for pulse
doses of 27 mGy shows a difference of 0.3%. From this
finding, the authors conclude that Jaffe plots may be an
appropriate method for determination of kS, but need
further investigation for higher pulse doses. However, all
findings must be seen in relation with the uncertainty of
2.1% in the author’s own determination of ks.
Bruggmoser et al. [76] modify the correction model by
Burns and McEwan [77] and determine general model
parameters (γ for the lack of charge collection and initial
recombination and a recombination parameter δ) for 8
ionization chambers (4 plane parallel, 4 cylindrical
chambers) from the analysis of chambers irradiated in
the pulsed photon and electron beams of conventional
medical electron accelerators. The modified Burns and
McEwan model with these parameters together with
chamber voltage and dose to water per pulse can be
used to calculate the recombination correction kS.
Calculations of kS with this method are found to be in
good agreement with published values for conventional
beams. The calculation was tested for pulse doses of
41.3 mGy and 41.7 mGy in the beam of a Novac 7 for a
Roos-type plane-parallel and a Farmer chamber (both
PTW Freiburg) by comparison with pulse-independent
thermoluminescence dosemeter (TLD) measurements.
The corrected IC measurements agreed with the TLD
measurements within 0.9% for the Roos and 0.3% for the
Farmer chamber. This correction method is recom-
mended for the 8 modelled detectors by the German
dosimetry protocol DIN 6800-2 [65].
In summary the publications give no clear answer
concerning the superiority of any of the models. The
use of ionization chambers with small electrode separa-
tions and a high bias voltage should keep the recombin-
ation losses small but this must be confirmed for every
installation.
Since the dose per pulse changes with depth in phan-
tom, the measurement of relative dose distributions such
as depth dose curves and profiles with an ionization
chamber requires depth dependent recombination cor-
rections. Therefore, measurement with selected diodes
which must be checked for pulse dose and energy inde-
pendence, are preferable.
Due to the uncertainties in determining the beam
quality and recombination corrections it is recommend-
able to confirm the calibration of IORT accelerators by in-
dependent mailed electron dosimetry from an accredited
calibration laboratory. Several calibration laboratories
provide mailed dosimetry (e.g. TLD dosimetry service is
provided by the IROC Houston Quality Assurance Center
[78], Fricke dosimetry service is provided by the Italian
INMRI [79], Alanine dosimetry by the British NPL [80]).
Investigations to confirm the independence of the mailed
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ment of additional services would be helpful. The correc-
tion factors found by comparison with mailed dosimetry
must then be adapted to all field sizes.
QA of electron IORT systems
Since IORT is applied in a single fraction of high dose,
the output of IORT systems must be verified on a daily
or even individual patient basis. Frequency of checks
should only be reduced after careful verification of suffi-
cient stability of the output. To fit into the busy time
schedule of an OR, and to limit dose workload to per-
mitted levels the dosimetric QA checks should be per-
formed in quick and easily reproducible procedures. A
check phantom which attaches to the end of a reference
applicator is described by Hensley [58]. Output can be
verified with an ionization chamber in one single depth
for all beam energies in order to avoid changing the set-
up. To additionally verify the beam energy, a measure-
ment can be performed in two predefined depths. How-
ever, such a check requires repeated changes of chamber
depth. A phantom allowing measurement at depth of
maximum and around 50% on the PDD curve together
with a dedicated QA applicator is supplied along with
the Mobetron (shown by Beddar [81]).
With the high electron dose rates from IORT accelera-
tors, charge accumulation in insulating (plastic) materials
can alter the current measured by an ionization cham-
ber [82–85]. Phantoms should therefore be constructed
from conducting material or composed as stacks of
slabs which locally accumulate only a negligible amount
of charge.
For the Mobetron, Beddar [81] reports output varia-
tions within ±2% for all 4 beam energies in a sequence
of 20 daily QA trials and a long term shift of calibration
between 1.1% and 2.3% over a period of three years. To
assess beam energy variations, he estimates the shifts in
the depth dose curves leading to measured variations of
the ratio Dmax/D50% measured with the dual depth phan-
tom mentioned above and finds shifts well within
±1mm. Other accelerators seem to be less stable in out-
put and possibly also in beam energy. Agostinelli et al.
[86] show a variation of daily output of ±5% for the Liac.
They find a correlation these variations to a control par-
ameter (COR, a measure proportional to the difference
between preset and measured dose per pulse) displayed
on the control console. Possible causes for the unstable
output that are in discussion, but have not been de-
scribed in literature so far could be recombination losses
in the monitor chambers which lie immediately behind
the beam exit window and are therefore exposed to ex-
tremely high dose pulses. This may be increased by the
low pulse repetition rate (10 Hz for 10 MeV beam, 35 Hz
for the 8 Mev beam) which leads to a low rate ofcorrection cycles in the dose rate stabilization possibly
leading to large changes in pulse dose in repeated correc-
tions which do not average out. The manufacturer states
to have improved the monitor system, however no reports
have been published so far. Another possible cause of in-
stability may be changes in beam energy visible in mea-
surements outside the depth of Dmax. These could be
caused by the flexible wave guide connecting the magne-
tron and the accelerator guide. With this construction the
wave guide will bend differently in different head positions
and thereby change its resistance which can possibly lead
to energy shifts. However, no reports concerning these
hypotheses were found in literature.
kV X-ray systems
The kV X-ray systems come pre-calibrated by the manu-
facturers with pre-commissioned sets of dosimetric data.
Parts of dosimetric commissioning are identical with
dosimetric QA checks. Additional checks are described
separately for each system.
Intrabeam
Commissioning
For the Intrabeam system an atlas of depth dose distri-
butions for every applicator is integrated in the control
software. Verification of dose distributions at distances
of a few centimeters or less from the radiation source
requires extremely precise positioning of source and
detector within less than 0.1mm. Arrangements with this
precision are difficult to implement in standard water
phantoms. Zeiss therefore supplies a special water phan-
tom with a source support which can position and move
the source horizontally and vertically with the required
precision and rotate it continuously by 360° with 8 preci-
sion positions in 45° steps. All movements are defined
and indicated in relation to two fixed chamber positions
(lateral and longitudinal) for a soft X-ray ionization
chamber (in older systems for a 0.2cm³ PTW 23342,
the same as used in the PAICH QA tool of the Intra-
beam system. Newer phantoms are provided with a
0.005cm³ chamber PTW 34012, Both chambers are
manufactured by PTW, Freiburg, Germany). Move-
ments are possible with or without applicator. The IC
is positioned in the phantom inside two horizontally ar-
ranged waterproof (Perspex) chamber holders with a
thin solid water entrance window facing the source.
The IC is delivered along with every system.
Dosimetry and QA
Recommendations for the dosimetry of low energy X-
rays are given in IAEA TRS 398 [63], AAPM TG report
61 [87], the code of practice published by the IPMB [88]
and the German Standard DIN 6809-4 [89]. These rec-
ommendations were primarily written for the dosimetry
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etry at the surface of a phantom. The reference dosimetry
of all three kV IORT systems (Intrabeam, Papillon, Xoft)
provided by the manufacturers or published independ-
ently deviates from these recommendations. Verification
by users is not straightforward and requires careful con-
sideration of the energy dependence of detectors in the kV
region, the choice of phantom materials and the applica-
tion of often unpublished corrections. Eaton [19] gives a
comprehensive and detailed description of dosimetry and
QA for the Intrabeam system which can be used as refer-
ence for further information.
Zeiss calibration of the Intrabeam system
Zeiss provides the Intrabeam system with a calibration
using essentially the setup published for the older PRS
system by Beatty et al. [17, 90]. Dose is measured in
water without applicator with a soft X-ray chamber
(PTW 23342, the same type as provided by Zeiss with
the Intrabeam) at depths of 3-45mm in steps of 0.5mm.
Measurements are performed in a water phantom (simi-
lar to the one provided to users by Zeiss) in which the
chamber is contained in an acrylic water protection with
a thin solid water beam entrance window at a fixed pos-
ition, and the source is moved with a precision drive.
The chamber is calibrated in air in terms of exposure, its
reading is converted to absorbed dose to water with a
conversion factor f = 0.881 mGy/R. For the half-value
layers (HVLs) between 0.1 an3 mm Al measured for the
Intrabeam (see Table 1 and section HVL Measurements)
the mass energy absorption ratios μen=ρð Þwater= μen=ρð Þair
governing the variation of f vary within around 2.6%
[87]; the beam quality correction specified by PTW is
1.000 in the region T30 to T50 (HVL 0.42-0.93 mm Al).
No corrections are documented by Zeiss for polarity or
the attenuation of the beam entrance window. The dos-
imetry protocols recommend the calibration of low en-
ergy X-ray beams at the surface of a semi-infinite water
equivalent phantom (providing full backscatter), AAPM
and IPEMB additionally recommend a correction for
perturbation of the radiation field by the chamber and
the changes of chamber sensitivity caused by the scatter
radiation from the phantom (named PQ,cham in AAPM
TG 61 [87]and kch in the IPEMB code [88]). Values of
kch recommended by IPEMB [91] for the PTW 23342
chamber and a semi-infinite phantom range between
1.01 and 1.07 for HVLs of 0.1mm Al and 1mm AL.
Eaton and Duck [43] measure values of around 1.05 for
the Intrabeam with 1.5cm and 5.0cm spherical applica-
tors at 3.8cm distance from the surface of a solid water
phantom. Zeiss does not document the use of such a
factor which in this case would be caused by the water
phantom and the acrylic holder surrounding the
complete chamber (notably the chamber has no guardring to exclude scatter). The depth dose curve measured
in the water phantom without applicator is fitted by an
analytical function in order to extrapolate the dose down
to the probe surface. The dose measured with the cali-
bration described above (at a depth not named by Zeiss)
is related to a second measurement with the user’s PTW
23342 ionization chamber in the PAICH QA tool de-
scribed in the section quality assurance. This allows out-
put control in daily QA. To determine the dose with an
applicator, a second depth dose curve with applicator is
measured with the same procedure as above with a qual-
ity controlled standard Intrabeam source owned by the
manufacture. The ratio of the two depth dose curves is
fitted to a second analytical function called the applica-
tor transfer function. Multiplication of the applicator
transfer function with the user’s depth dose curve gener-
ates the depth dose curve with applicator at the user site
and via PAICH measurement relates the output to the
dose. With this method the minimum uncertainty is
stated as 4.2% for a dose measurement at precisely 2cm
depth in water and 5.3% at other depths due to position-
ing uncertainty and change of chamber response with
depth. In this way Zeiss provides a reproducible system
with reliable quality control in which applicators and X-
ray sources can easily be interchanged. A drawback is
that it is difficult to relate an independent dose measure-
ment to the daily QA measurement with the PAICH. To
verify the output and depth dose curves, Zeiss provides
correction factors with which the reading of a smaller
air-Kerma calibrated PTW 34103 ionization chamber
provided together with the water phantom is multiplied.
The factor converts the measured “non-Targit dose” to
“Targit dose” as it is applied in the Targit breast treat-
ments [92]. The correction factors are depth dependent
and vary between 0.5 at 3mm (0.77. at 7.5mm) and 0.9
at 45 mm distance from the source. Their uncertainty is
stated as around 6.7%. Zeiss explains that the factors
correct for a combination of three effects. 1: a different
effective point of measurement in the two ionization
chambers caused by the different solid angles of beam
seen by the 34013 and the 23342 chamber due to their
entrance foils of 2.9 vs. 5.2mm diameter (leading also to
the distance dependence). 2: Different designs of the
chamber holder producing different measured dose
rates. Zeiss states that this is particularly noticeable with
small source distances. 3: the different calibrations of the
23342 chamber in terms of exposure and the 34103
chamber in air Kerma. Zeiss states that the different
conversions of exposure or air Kerma to absorbed dose
to water by factors of f = 0.881 mGy/R (23324) or
kKa→Dw =1.036 (34103) leads to a constant offset in the
entire measuring range. From the Zeiss statements it is
not clear which of the measured quantities corresponds


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hensley Radiation Oncology  (2017) 12:37 Page 16 of 30
Hensley Radiation Oncology  (2017) 12:37 Page 17 of 30of them does). The explanation conflates different causes
for the correction factors and no publications are named
for their confirmation. Therefore, a confirmation of the
Intrabeam dosimetry system by independent methods is
highly desirable. Supported by Zeiss, the German stan-
dards laboratory PTB (Physikalisch-Technische Bunde-
sanstalt, Braunschweig, Germany) is developing a
primary standard for kV dosimetry which should pro-
vide the correct values of the doses delivered by the
Intrabeam system [93].
Independent dosimetry
A number of independent dose measurements in different
set-ups have been published of which some show discrep-
ancies with the Zeiss calibration.
Dosimetry protocols recommend the calibration of
soft X-ray beams (10-100kV, half value layer HVL < 1-
3mm Al) in air at the surface of solid or water phan-
toms, and not in depth in water due to the uncertainties
in positioning and the uncertainties in attenuation and
perturbation by the waterproofing of soft X-ray detectors
[63, 87–89].
Publications on dose measurements
The first report by Beatty et al. [17] on reference dosim-
etry for the older type of the PRS system measures the
dose (without applicator) at 10mm depth in water with
an older type (PTW 30-334) of the soft X-ray chamber
provided by Zeiss (PTW 23342). The chamber is cali-
brated in air in terms of exposure. As in the Zeiss cali-
bration, its reading is converted to absorbed dose to
water with a Roentgen-to gray conversion factor (f )
without any of the corrections for differing beam quality
(PQ), ion recombination (Pion), or polarity (Ppol) recom-
mended in the later dosimetry protocol AAPM TG 61
[87]. During the measurement the chamber is contained
in a waterproof acrylic housing with a thin solid water
window. No corrections are made for changes of the
scatter radiation caused by the acrylic holder or the
changes of amount or spectrum of the direct radiation
through the window (which are partially included in the
Psheath correction in AAPM TG61 [87]). Correction fac-
tors for homogeneous PMMA, nylon and polystyrene
sleeves surrounding a Farmer (thimble type) IC are re-
ported by Ma and Seuntjens [94], however no reports
were found for sleeves with a thin solid water entrance
window. The authors estimate an overall uncertainty of
±10.2%, resulting mainly from the positioning uncer-
tainty with a contribution ±2% from the IC calibration
and ±1% from the conversion factor f.
Ebert and Carruthers [42] report a verification of IC
measurements in water in the same set-up as the Zeiss
calibration by simulations with an analytical beam model
and Monte Carlo calculations. They show that due tospectral changes, the ratio of mean mass-energy absorp-
tion factors of water to air (which determines the energy
dependent response of an ionization chamber) decreases
by about 2.2% between the surface of the bare source
and 3-4cm depth in water. Monte Carlo calculated depth
dose curves with applicator in comparison to curves
measured by the manufacturer show good agreement,
however there is discrepancy in the change of dose rate
altered by larger applicators in relation to the dose rate
of the bare probe.
Eaton and Duck [43] describe a method of calibrating
the system using the IPEMB protocol by calibrating an
ionization chamber and radiochromic films (EBT) in air
with a second X-ray device with similar HVL (see section
HVL measurements below), including a determination of
chamber correction factors kch. They use these calibra-
tions for reference dose measurements at the surface of a
solid phantom (Solid Water WT1) with the IC. Relative
dose distributions in water are measured with film and IC
in a water phantom. The paper states no value for the
uncertainty of reference dosimetry, however differences
within 6.9% between IC and film measurements. The
differences between film and manufacturer data are up to
4.8% at distances larger than 10mm from the applicator
surface and up to 8.8% at distances less than 10mm. It is
not clear if these differences relate to the absolute dose
values stated by the manufacturer or the normalization at
10mm distance from the applicator surface. The authors
attribute the differences mainly to uncertainty in posi-
tioning in the steep dose gradient but the difference in
film response between the calibration in air and the
measurement in the hardened spectrum in water should
be considered as a possible cause.
Dose verifications with in-vivo dosimetry
Two publications on in-vivo dosimetry attempt to verify
the dose delivered by the Intrabeam system and find
large deviations:
With EBT2 film, Avanzo et a. [95] report in-vivo
measurements in 23 patients at the surface of Intrabeam
applicators which differ from the doses specified by the
Intrabeam software on average by -27.6%, -19.9%, -11.9%
and -10.4% for the 3.5cm, 4.0cm, 4.5cm and 5.0cm appli-
cators. The films are calibrated with the 3.5cm Intra-
beam applicator (at 50kVp acceleration voltage) in air by
comparison with measurements with a PTW 23324
ionization chamber. The authors assume that incomplete
adherence of film and applicator or incorrect positioning
of the detector may be the cause for the deviations. It is
not reported if corrections were made for dose averaging
on a flat film irradiated in the steep and divergent gradient
around the spherical applicator which may have caused a
reduced signal. Similar deviations are found by Price et al.
[96] with measurements in 20 patients at the applicator
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stimulated light emitting dosimeters). Dose differences
found with films were +6.3%, -7.3%, -11%, -16.6% at the
surface of the 3.0cm, 3.5cm, 4.0cm and 4.5cm applicator,
with OSLDs: -1%, -21% -30% and-13.6% at the surface of
the 3cm, 4cm, 4.5cm and 5cm applicator. Both films and
OSLDs are calibrated in water in the beam of the 4cm
applicator (at 50 kVp) by comparison with measurements
with a PTW 34013 chamber. It is not documented if the
readings of the chamber were corrected with the Zeiss
factors (or if these factors were available at the time of
publication in 2010). Again it is not documented if dose
averaging effects on the film were corrected. Although in
the results of both publications a number of uncertainties
must be considered (adherence of the detector to the
applicator surface, energy dependence of the detector,
volume averaging, tissue displacement by the OSLDs), also
calibration uncertainties of the Intrabeam system should
also be considered as possible cause of the differences.
Summary: Intrabeam dosimetry
A number of uncertainties remain in the reference dos-
imetry of the Intrabeam system which require clarifica-
tion. Publications of reference dosimetry are needed
with an applicator in water using the ionization chamber
and water shielding sheath provided by Zeiss and also a
check device to quickly verify the PAICH dosimetry
would be helpful. A Perspex phantom which is attached
to the Intrabeam probe could possibly be calibrated for
this purpose is described by Armoogum and Watson
[97]. It must be stressed that the uncertainties do no
not preclude therapeutic use of the system, since the
dosimetry system currently recommended by Zeiss
applied by the users is empirically proven as safe and is
efficient within the assumptions of the Targit and other
trials. In case a correction of the “Targit dose” to a
different physically defined absorbed dose is needed,
this may not lead to a change of dose prescription until
medically justified. However, a clear correlation of “Targit
dose” to physical dose is important to understand dose-
effect relationships and to compare Intrabeam treatments
with other methods.
Dosimetry of the Papillon system
In general, the same considerations and methods should
apply for dosimetry of both the Papillon and the Intra-
beam system. For this system, Carver et al. [98] investi-
gate the conditions for dosimetry with Monte Carlo
calculations and calculate chamber corrections kch and
backscatter factors. Croce et al. [28] compare Monte
Carlo calculated dose distributions in PMMA and
water with relative dosimetry using a plane parallel
ionization chamber (PTW 23342, PTW Freiburg) and
EBT2 radiochromic film in a PMMA phantom. Thechoice of PMMA as phantom material may be a source
of uncertainty as shown by Schönfeld et al. [99]. Due
to its higher density of 1.19g/cm3, dose distributions in
PMMA can differ considerably from those in water,
depending on distance from the source and also on
phantom size.
General aspects of kV dosimetry
HVL measurements Due to the energy dependence of
the response of most detectors, care must be taken to
calibrate in a similar radiation quality as the measured.
The response of most dose detectors depends on photon
energy, and the parameter recommended by the dosim-
etry protocols to describe the beam quality is its half
value layer (HVL) in aluminium. For some detectors,
manufacturer document energy dependent response in
terms of the photon energy. As shown by Chofor et al.
[100], for many detectors and for energies above 100
keV the mean energy of the fluence spectrum determines
the energy response. Table 1 summarizes published mea-
surements of Intrabeam HVL of and shows that there is a
substantial variation depending on surrounding material,
applicator and distance from the source. Zeiss [90] pro-
vides measured HVLs at 10mm depth in water (apparently
without applicator) for the type 4 X-ray source (XRS) of
the Intrabeam together with corresponding effective ener-
gies Eeff and beam qualities as used by PTW Freiburg for
the calibration of the PTW 23342 0.2cm3 plane-parallel
ionization chamber (IC) (PTW Freiburg, Germany) which
is supplied along with the Intrabeam system. For an accel-
eration voltage (AV) of 50 kV, Zeiss states an HVL of 0.64
mm Al, corresponding to Eeff = 20.4 kV or a beam quality
index between T30 and T50 (for AV = 40kV : HVL =
0.48mm Al, Eeff = 19.1 kV, ≈T30; for AV = 30 kV: HVL =
0.41 mm Al , Eeff = 17.3 kV, ≈T30) [90]. Although this is
not explicitly indicated by Zeiss, these values probably
apply to the bare probe surrounded by water. Measured
half value layers (HVL) for the Intrabeam system have
been reported by several authors [17, 18, 43, 95, 101]
showing the massive spectral changes by beam hardening
in the applicators and in tissue (or water) which are
already shown in air in the report by Beatty et al. [17].
Table 1 compiles the half value layers and mean energies
published by various authors and shows that the beam is
substantially hardened by the applicator and by increasing
depth in water.
For the unattenuated beam, Beatty et al. [17], Armoogum
et al. [18] and Avanzo et al. [95] report HVLs of 0.1-
0.11mm Al. With the source inside the breast applica-
tors, Eaton and Duck [43] report 1.3 mm Al for the
3cm applicator, 0.85mm for the 3.5cm, 1.24-1.25mm
for the 4.5cm and 1.26-1.29mm for the 5cm applicator.
Avanzo et al. [95] report: 0.8mm (3cm appl.), 0.98mm
(4cm appl.), 1.1mm (4.5cm appl.) and 1.23mm (5cm
Hensley Radiation Oncology  (2017) 12:37 Page 19 of 30appl.). For the bare source behind 1cm solid water,
Beatty et al. [17] report an HVL of 0.71mm Al, and
Armoogum et al. [18] report 1.11mm Al. Anvanzo et al.
[95] report 1.75mm Al at 1cm depth in solid water,
2.14 mm at 2 cm depth in solid water and 3.82mm
behind a tungsten shield for a source in an applicator.
The compilation in Table 1 shows that HVL and mean
energy are different at practically any two measuring
positions. This causes the need of dosimetry detectors
with response independent of photon energy in the re-
gion of 1-50 keV and makes the comparison of different
methods of calibration of the system difficult.
Dosimetry with radiocromic film A number of the
publications on calibration, measurement of dose distri-
butions and in-vivo dosimetry for kV-X-ray devices
report the use of radiochromic film, many using types of
film which are known to have a strongly energy
dependent response in the low energies occurring with
these devices [95, 101, 102]. Recent publications show
that the response of EBT film in comparison to a calibra-
tion in Co-60 increases from -39% at 20 keV to around
-18% at 40 keV [103], the first value corresponding to
the mean X-ray energy at the surface of the bare Intra-
beam source (in air). In the region 20 keV to 25 keV
(corresponding to the effective energy at the surface of
the Intrabeam applicators) the energy response would
then vary between -40% and -35%. This variation of lo-
cally around 14% could have caused part of the differ-
ences between Zeiss specifications and measured depth
dose curves found by Eaton and Duck. Ebert et al. [101]
find a similar dependence of response of EBT films be-
tween 0 and 30mm distance from the Intrabeam probe
in water and conclude that this film is not suitable to
obtain quantitative dosimetry information at the low en-
ergies involved here. Avanzo et al. [95] show calibration
curves of EBT2 film for 6MV photons and 50kV pho-
tons measured with the bare Intrabeam probe in air
(HVL = 0.11 mm Al) in which the optical density differs
by about 10%. A second set of measurements in the
beams of 3.5cm and 5cm applicators showed no signifi-
cant energy dependence in the corresponding energy
range (3.5cm applicator: HVL 0.8mm Al, mean energy
10.2 keV; 5cm applicator: 1.23mm Al, 25.1 keV). A re-
port on the energy dependence of EBT and XR-QA
radiochromic films to kV in comparison to MV photons
is given in the report by Chiu-Tsao et al. [104]. Uncer-
tainty in the reading of radiochromic film is strongly in-
fluenced by the selection of scanner and the scanning
procedure. General recommendations for the use of
radiochromic film are given in the report of AAPM TG
55 [105] , detailed reports on film handling and reading
of optical density for radiochromic films used in IORT
are given by Avanzo et al, [95], Ebert et al. [101], Cioccaet al. [106], Price et al. [96], and Severgnini et al. [107]. It
is important that the type of radiochromic film is reported
in publications, and care should be taken to use films and
other detectors with appropriate energy response. Over-
views of different films used in IORT are given in the re-
ports by Eaton [19] and Ebert et al. [101].
Thermoluminescence Dosimetry Soares et al. compare
dosimetry of the Intrabeam with thermoluminescense
dosimeters (TLDs) and two ionization chambers in a
water phantom. IC reference dosimetry is performed
under thin layers of water equivalent plastic. They find
reasonable agreement between the results with the two
detectors and estimate an overall uncertainty of 8-13%
for the TLD measurements, however make no compari-
son with the Zeiss dosimetry [108]. This publication and
also Eaton et al. [109] report assessments of the energy
dependence of the response of TLDs in the energy
region of kV-IORT and find variations of around 29%
[108] and 6-9% [109] for LiF:Mg,Ti and around 98%
for LiF:Mg,Cu,P [108].
Phantom materials for low energy X-ray devices As
described by Eaton [19] in more detail, the correct selec-
tion of phantom material for dose measurements of low
energy X-rays is crucial since dose deposition is domi-
nated by photoelectric absorption and therefore very
dependent on material composition. Additionally, the X-
ray spectra can change differently with distance from the
source in the phantom (or applicator) material and in
water. An investigation by Schönfeld et al. [99] for Ir-
192 shows that the depth dose distributions in many
solid phantom materials considered as water equivalent in
external beam therapy can considerably differ from water.
The spectral changes for photons with energies > 100 keV
are mainly caused by increased scatter from Compton in-
teractions, so that the mean energy will decrease. For low
energy X-rays the mean energy will increase by stronger
photoelectric absorption of the lowest energy photons.
This will probably lead to different depth dependent varia-
tions of dose deposition in material which may not be
negligible and need further inspection. For Ir-192, suitable
commercial materials requiring a dose correction of
less than 1% for measurements up to distances of about
5-10cm in phantoms with dimensions smaller than
20cm radius are Plastic Water LR, Plastic Water DT
(both CIRS, Norfolk, VA), RW1 and RW3 (both PTW,
Freiburg, Germany). The same phantom materials are
quoted by Eaton [19] for investigations with the Intra-
beam system. Both authors find that Perspex should
not be used as phantom material due to its higher
density and backscatter. The same considerations as for
phantoms hold for the material of the waterproofing
sheath for an IC used in a water phantom.
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dose and dose distributions for kV X-ray systems are
difficult and care must be taken in the selection of
detectors and phantom materials with small energy
dependence in the range of 10-50 keV or appropriate
corrections. The photon spectrum changes for each ap-
plicator and additionally with distance from the source.
Care must be taken to select a radiation quality for cali-
bration for which detector sensitivity can be corrected
to the measured quality. Further publications would be
helpful both on detector calibration and on manufac-
turer independent dosimetry of the kV systems with
applicators in water.Quality assurance The Intrabeam system is delivered
with a calibration by the manufacturer and includes two
tools for daily QA, the PDA (Photodiode Array) and the
PAICH (Probe Adjustment and Ionization Chamber
Holder). Both tools are self-shielding (the drift tube with
the X-ray target is completely inserted into the tools)
and allow QA in an unprotected environment with negli-
gible exposure to the operator. The PDA contains 5 diodes
arranged around the tip of the drift tube (4 in the horizon-
tal plane, one in front) which measure the isotropy of out-
put and can be used for electronic adjustment of beam
deflection. If anisotropy larger than the pre-set tolerances
is detected, the drift tube (probe) can be mechanically ad-
justed in the PAICH tool. Here the position of the source
tip is inspected with a light source and photo diode and
can be manually aligned with a plunger. The PAICH also
has a shielded insert for a PTW 23342 soft X-ray chamber
(supplied with the system together with a PTW Unidos E
electrometer) with which the source output is measured
and the internal radiation monitor (IRM) is calibrated. The
IRM is a photodiode detector in the source housing which
continuously measures source output. Temperature and
air pressure corrections are performed automatically by
the control system. Tests of isotropy and output can be
performed in around 10 minutes and are required before
every new patient together with a number of administrative
and safety checks. The checks are controlled and recorded
automatically by the system computer during patient
set-up. Note that the QA tests verify only the output in
air, to which the dose in water with or without applicator
is so far only related by the manufacturer calibration.
Additional to the daily tests, Eaton [19] recommends a
number of procedures at longer intervals including six-
monthly reassessments of environmental dose and checks
of chamber constancy, annual tests (or following system
service or re-calibration) of beam steering, monitor
linearity and measurements of source output in water
or solid phantom and source isotropy and depth dose




Reference dosimetry for the Xoft Axxent X-ray source is
based on an air Kerma-rate standard at 50cm from the
source provided by the national American dosimetry
standard laboratory NIST [110]. DeWerd et al. propose
a modified TG43 dose calculation protocol [32] in which
the absorbed dose-rate to water at the TG43 reference
point, _Di 1cm; π2

) , is calculated as the product of the
air Kerma-rate at 50cm source distance _K 50 with an
applicator-dependent dose-rate conversion coefficient
χ i ¼ _Di 1cm; π2

)/ _K 50 wherein the index i designates the
applicator [111]. The University of Wisconsin Accre-
dited Dosimetry Calibration Laboratory (UWADCL)
will use these dose–rate conversion factors to provide
calibrations of the well chamber (HDR-1000; Standard
Imaging, Middleton, WI) which comes with every Xoft
Axxent system. For the water-like balloon applicators
used in breast IORT, the TG43 data published by Rivard
et al. can be used [32]. These are measured and calcu-
lated for water surroundings without applicator and for
source voltage settings of 40 kV, 45 kV and 50 kV. For
some applicators (e.g. titanium cervix applicators) also
provided by Xoft , applicator-specific radial dose func-
tions gi(r) and anisotropy functions Fi(r,θ) as defined in
the modified TG43 dosimetry protocol must be used.
With the well chamber, the output of the individual
source is measured before clinical use and before every
treatment. With this source calibration and the TG43
data, treatments can be planned with a commercial plan-
ning system supporting TG43 calculations. The paper by
Rivard et al. [32] also describes a calibration of the Xoft
source in a precision positioning water phantom with a
plane plate IC (PTW 34013, PTW Freiburg, Germany)
housed in a solid water waterproofing. Calibration of the
chamber is traceable to the German National Standard
Laboratory PTB (Physikalisch-Technische Bundesanstalt,
Braunschweig, Germany). For this reference dosimetry
in water, Rivard et al. [32] state an uncertainty of 4.6%,
the uncertainty of the dosimetric parameters is stated as
4.7% at 1cm and 8.2% at 5cm distance from the source.
Together with an estimated uncertainty of 2% for the
calibration of the well chamber, quadratic addition yields
a total uncertainty of 6.6% at 1cm and 9.4% at 5cm
distance. Table 1 shows the HVL and mean energy of
the Xoft Axxent as reported by Liu et al. [112].
Quality assurance
The Xoft Axxent system is supplied with a physics and
QA accessories kit which includes a phantom
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acrylic phantom contained in a shielding which allows
irradiation in the fixture with minimal exposure to the
outside. The middle slab is 5.2mm thick and has a cen-
tral drilling that can accommodate the source (diameter
3.2mm) covering the source by 1mm of acrylic. A grid of
radiopaque position markers on the slab allows inspec-
tion of correct source end position and pullback visually
or by exposing a radiochromic film. By placing a sheet
of radiochromic film on the opposite top of the source
guiding slab, exposure distributions can be recorded to
verify e.g. source pullback or the isotropy of the dose.
Caution should be taken in relating the film signal to
dose distributions since, as discussed for the Intrabeam,
energy response of radiochromic film is energy
dependent and spectral changes in a PMMA phantom at
different distances from the source (as shown by Schön-
feld et al. for an Ir-192 brachytherapy source in water
[99]) may cause additional changes in response. The bot-
tom slab of the phantom contains an accommodation
for an ionization chamber, placing it at a position below
the center of the source drilling. An assignment of the
chamber reading to absorbed dose to water is uncertain
(and not mentioned in the manufacturer documenta-
tion) due to unclear absorption, spectral changes and
scatter conditions pertaining to the low energy X-rays
which may cause changes in the chamber response (as
shown by Chofor for Ir-192 sources [100]). Additionally,
tools are provided to ensure correct source positioning
in an applicator by measuring the length of the individ-
ual source arrangement (source plus guiding structure),
the length of the source channel in the applicator (“ap-
plicator depth”) and to calibrate the outdrive and step
length of the source retraction (“pullback”) mechanism
on the controller arm. Such tests and adjustments are
needed before patient treatment for every new source
and applicator. Output is measured in the well chamber
before every treatment; the standard deviation of dose
rate for a given source during a series of measurements
was found by Rivard et al. [32] to be < 0.3% at all operat-
ing voltages.
In-vivo dosimetry (IVD)
For both IORT modalities, electrons and kV-Xrays, a large
number of examinations have been published dealing with
in-vivo dosimetry, possibly indicating a need for better
information in IORT dose and dose distribution. As
detectors, MOSFETs [86, 113–118], radiochromic film
[106, 107, 115–118, 119], optically stimulated lumines-
cence detectors (OSLDs) [96] and TLDs [118, 120] have
been used, in one publication the use of semi-conductor
diodes is reported [121]. Additional file 1 gives a compil-
ation of the publications showing the detectors and their
uncertainties as stated by the authors, the investigatedtreatment sites and the measured quantity, and highlights
the detected deviations from the expected dose. Some au-
thors derive action levels for correction of the treatment
setting which are also shown in the table. Details of the
table items are discussed in the following sections, the de-
viations between expected and measured dose for kV irra-
diations are discussed in the section on dose verification
by in-vivo dosimetry of the Intrabeam system.
Detector selection and uncertainty for in-vivo dosimetry
In addition to the requirements discussed in the sections
on dosimetry i.e. small statistical uncertainties, a small
energy dependence of response, especially in the kV X-ray
region and the selection of a comparable radiation quality
for calibration, detectors for in-vivo dosimetry in IORT
must have a number of special properties connected to
their measuring position inside the patient tissue. Criteria
for detector selection in in-vivo dosimetry are small size
(in order to place it inside the surgical cavity or even a
catheter), its ability to be sterilized, and also a small
temperature dependence, since calibrations are normally
performed for reference conditions (20 °C) and measure-
ments at body temperature (37 °C).
For MOSFETs, uncertainties in response between 1.5%
and 5% are reported (all for electrons) [113–116, 122].
For these detectors, two publications report a dependence
of response on the angle of radiation incidence of up
to >15% at 45° and 24% at 90° which can also contribute
to uncertainty [115, 122].
With radiochromic film, uncertainties of around 3%
are reported for electrons [106, 117, 118]. For kV X-rays
one would expect larger uncertainties due to the energy
dependence of film and TLDs discussed in the section
on kV dosimetry which depends on type of film . Avanzo
et al. report a reproducibility of 2.8% of the reading of
EBT2 films calibrated in air at 30mm distance from the
bare probe of an Intrabeam irradiator [95, 97].
The energy dependence of the response of TLDs in
the energy region of kV-IORT is reported in three publi-
cations [108, 109, 123] and discussed in the respective
section on general dosimetry of kV X-ray systems.
Price et al. [96] investigate the energy dependence of
OSLDs and RTQA2 radiochromic film in the strongly
varying spectra of kV X-ray units by measuring at several
fixed distances from two Intrabeam applicators of differ-
ent diameter. They find changes in response of OSLDs
between -6.6% and 2.8% at 0.15mm distance from the
applicator surface and between -16.5% and 3% at 1cm and
2cm distance. For RTQA2 radiochromic film they find
differences in responde between -6.8% and 6.2% at the
surface and -1.8% and 8% at larger depths.
A source of uncertainty may be the distortion of the
radiation field by the detector. Consorti et al. [115] report
an increased attenuation of up to 20% for 4 MeV electrons
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detector contained in a plastic catheter. For RTQA2 films
in a solid water phantom, Price et al. find dose reduction
of 8.5% at 5mm distance from the needle tip decreasing
with distance to 2.6% at 2cm distance [96]. For OSLD
detectors they find an increase in reading between 4.1 and
20.5% caused by fact that the rather large housing of the
detector has a lower density than the water it displaces.
For in-tissue measurements they suggest to consider only
the increased absorption of 5.9% by the detector itself
since the housing mainly displaces tissue and due to
its reduced absorption causes a smaller change to the
surrounding local dose.
All mechanisms listed above may contribute to the
uncertainty and the dose deviation found in in-vivo
dosimetry.
Action levels
Several of the publications on in-vivo dosimetry of IORT
with electrons report entrance dose measurements some
of which are apparently aimed at correcting for the
unstable output of some machines [86, 106, 113, 114].
For such measurements, the action level at which one
should consider to correct the monitor preset can be set
equal to the uncertainty of the detector system. A num-
ber of authors derive action levels of around ±6-7% from
their examinations, above which a correction of treat-
ment parameters should be considered [86, 113, 115].
For measurements in depth of tissue, often larger devia-
tions from the expected dose are found than the uncer-
tainties stated for the different detectors (which range
between 1.5 and 5%). Mean deviations are typically shifted
by a few per cent from expected dose, standard deviations
range between 3.5% and 9.9%, and often single deviations
are substantially larger than the detector uncertainty (out-
liers). The authors often explain the deviations by inexact
positioning of the detector, miscalculation of monitor
units (incorrect determination of target depth?) or in-
creased absorption of radiation from bleeding. Severgnini
et al. [107] report measurements with larger pieces of
radiochromic film which were placed on top and below
shielding disks used in breast treatment with electrons. By
visual inspection of the films they can detect misplace-
ments of the disk or misalignments of applicator and tar-
get, and by quantitative analysis find dose reductions by
30% in 2 patients, possibly caused by incorrect determin-
ation of target thickness, additional absorption by blood
or incorrect matching of applicator and target. The as-
sumption of errors in set-up or detector positioning is
supported by two publications which report smaller devia-
tions for entrance dose than for dose in depth [115, 119]).
López -Tarjuelo et al. [118] develop a model to calculate
probability density distributions and confidence intervals
for the dose measured with MOSFET and radiochromicfilm detectors from the convolution of a probability distri-
bution of detector response with the expected dose distri-
bution (similar to the convolutions used in small field
dosimetry). A measured dose deviation exceeding the con-
fidence interval could then be considered to lie beyond an
action level. In 30 measurements of dose to the tumor bed
of 29 patients (delivered with electrons from an Elekta
Precise accelerator) they find confidence interval widths
between 8.6% and 14.7% around the expected dose level
of 90% PDD. Using these widths as action level they find
37% outliers. For dose measurements in depth, IVD is ap-
parently very uncertain, and it is questionable whether
one can define meaningful action levels.
Controlled procedures for placement of in-vivo dosimeters
To reduce uncertainties in the in-vivo dosimetry set-up,
controlled institution-specific procedures should be de-
veloped, e.g. to pre-plan IVD, and to instruct and train
the involved (sterile) personnel how to correctly place
and fix the detectors. Imaging of detector position, e.g.
with ultrasound should help assigning detector position
to measurement results. Publications of reliable proce-
dures reducing uncertainty would be of help.
Treatment planning, in-room imaging
Despite the named uncertainties in detector response
and positioning, the results of in-vivo dosimetry indicate
that that deviations from intended dose are present in
IORT. Since, with exemption of a few in-house devel-
oped systems, no real time treatment planning for IORT
is available, treatment is generally based on the concept
that the dose distributions from an isodose atlas mea-
sured in a simplified set-up with the applicator posi-
tioned flat on a body of water (or a closely adherent
body of water for the spherical applicators used in kV
IORT) also apply in the patient. This is clearly not true.
Gaps between applicator and tissue as well as the non-flat
surface change the distance from the source. Collection of
blood and other liquids on top of the tissue changes the
target depth. Heterogeneities inside and adjacent to the
radiation field, e.g. bones, air gaps or also shielding mate-
rials change radiation absorption and also scatter con-
tributions. Additionally, the shape, dimensions and also
the position of the target in the beam are not documented
and often not completely known. The key developments
of recording and planning therapy on images which lead
to the major improvements of radiotherapy in roughly the
last 35 years have practically not taken place in IORT.
These uncertainties are usually acceptable in the classical
approach of IORT to treat a thin superficial layer of target
tissue, however can lead to significant errors when ex-
tended (thick) target volumes are treated which cannot be
seen in total by surgeon and radiation oncologist e.g. in
breast IORT.
Fig. 9 The robot-mounted flat panel surgical imaging device
Siemens Artis zeego (Siemens Healthcare GmbH, Henkestr. 127,
91052 Erlangen, Germany)
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Major reasons for the lag in development of planning
systems for IORT are the unsolved difficulties in install-
ing useful in-room imaging in the OR. Devices providing
the three-dimensional images used in modern treatment
planning interfere with the limited space in an OR, con-
sume additional operation time, and are difficult to pos-
ition conserving the sterile surgical set-up. The patient
often has an unfavorable and space-consuming position
which makes placement of the imaging device and correct
adjustment in relation to the target difficult. A sometimes
unavoidable problem of intraoperative imaging is the
image artifacts caused by metallic surgical tools and table
parts. Replacing them by non-metallic materials is often
not possible. Additionally, in-room imaging causes instal-
lation costs which are difficult to justify for a limited IORT
program usually treating only a small number of patients
per week. A strategy to improve the cost-efficiency of
imaging devices may be to plan for special ORs which
provide 3D-imaging for multiple purposes together
with IORT.
Although CT on rails technique is becoming present
in radiotherapy vaults [124, 125] only one facility (in
Klagenfurt, Austria) was found in this review providing
this service in an IORT room. For In-OR imaging cone-
beam CT (CBCT) facilities on mobile C-arm surgical
fluoroscopy units have been developed [126], however
these can often only reconstruct a small image volume
which is difficult to position around the IORT treat-
ment volume. Easier positioning is possible with the O-
arm CBCT (Fig. 8). Larger reconstruction volumes and
easier positioning in the OR setup are provided with
newer C-arms which combine large flat panel detectors
with robotic positioning (Fig. 9). A promisingFig. 8 The O-arm mobile surgical cone beam CT imaging device
(Medtronic GmbH, Earl-Bakken-Platz 1,40670 Meerbusch, Germany)development is the PAIR system in development by the
Salzburg Paracelsus Medical University in cooperation
with MedAustron (Fig. 10) [127, 128]. The patient
couch is mounted on a ceiling-mounted robot arm to-
gether with a large bore (60cm) sliding imaging ring.
After loading (or possibly also operating) the patient on
the couch, the ring is moved over the patient and ac-
quires CBCT images with a large flat panel detector.
Patient dose can be reduced by image reconstruction
from only a limited part of the field of view. From the
loading position the patient is moved with the roboticFig. 10 The PAIR patient alignment imaging ring (medPhoton
G.m.b.H., Müllner Hauptstraße 48, 5020 Salzburg, Austria)
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accelerator without repositioning on the couch.
An issue in using CBCT images for radiotherapy treat-
ment planning is the larger uncertainty in the assignment
of electron densities to CT-numbers [129] which is larger
than for conventional fan-beam CT. This can result from
different image acquisition parameters such as voltage
settings but also depends on the different scatter contri-
bution from different scanned volumes in different parts
of the body [130]. Scatter causes a larger background of
noise and streak and cupping artifacts in reconstruction
[131, 132]. Strategies to reduce calculation errors from
incorrect densities may be the use of multiple calibration
curves for different sites [130, 133], manual assignment
of densities to segmented tissue regions, mapping elec-
tron densities form conventional CT to CBCT [134] or
matching the applicator and target position from an in-
room CBCT to a previously acquired conventional CT
and using this for planning.
Treatment planning systems for IORT
So far, there is no commercial treatment planning system
which uses in-room imaging. The single existing system
for IORT planning [135] combines a surgical navigation
system with elaborate tools for volume rendering of CT
images with the possibilities to simulate a surgical cavity,
define an applicator in position and angle, and calculate
the dose distribution. This can be used to pre-plan the
surgical IORT procedure or to reconstruct the dose distri-
bution, usually on an independent CT study. For electron
dose calculation the system uses a pencil beam model. A
Monte Carlo based model is in development using phase
space files of the electron fluence at the applicator end as
source model. In a second line of development the system
a hybrid Monte Carlo model (“dose painting”) [136] is
used to calculate dose distributions for low energy X-rays
from Intrabeam applicators. Additionally the system pro-
vides reporting tools and can be connected to verify and
record systems including DICOM RT export. In summary,
further developments in IORT in-room imaging and in
treatment planning are needed.
Reporting IORT
In lack of a planning system and computerized tools for
documentation, manual records of IORT are essential.
These should include all information necessary to recon-
struct the anatomical site and distribution of dose at a
later time, e.g. to plan additional external beam radio-
therapy or to correlate a recurrence with the first treat-
ment. Therefore the record should include anatomical
sketches showing the treatment site and possible shielded
areas, applicator size and location including the angle of
beam incidence, beam energy, information on bolus, gaps
or any circumstance altering the dose distribution. Forlater evaluation and pooled analysis, participation in IORT
registries is helpful.
Uncertainties and deviations from intended dose in IORT
The possible deviation of the dose applied in IORT from
the desired value can be caused in part from the uncer-
tainty in its physical determination. This is composed of
the uncertainty in the reference dosimetry (calibration)
with which the absolute output of the irradiator is mea-
sured, the uncertainty in the measurement (and recording
etc.) of the dose distributions and the reproducibility of
the output between a calibration and a treatment or re-
peated measurement at a later time. If one restricts this
consideration to absorbed dose to water, no uncertain-
ties in the transformation of dose to other materials or
biological doses occur. An additional source of uncer-
tainty stems from possible deviations from the intended
set-up. If the detector is placed correctly, this compo-
nent, together with the reproducibility of the output and
the uncertainty of the measurement is the major source
of the dose deviations seen in in-vivo dosimetry. A third
source of dose deviation is caused by the inhomogen-
eous dose distributions applied in IORT. Although this
component is not an uncertainty it also contributes to
the dose differences which determine the different out-
come of two treatments (by the same or by different
techniques). All of these components are considered in
the following discussion in order to estimate a general
number for the probable dose deviation, and to identify
the physical means with which the deviations can be re-
duced. Additional file 2 compiles/summarizes the devia-
tions found in this review for IORT with electrons and
for kV X-rays and calculates the range of probable total
dose deviations (Devtotal) by summing the components
in quadrature. Additional file 2 summarizes the uncer-
tainties and dose deviations described below in detail.
IORT with electrons
Due to the non-reference conditions, uncertainty in the
calibration of IORT electron beams is slightly larger than
the uncertainty of 2.1% estimated by IAEA TRS 398 [63]
for external beam accelerators. For the output of beveled
applicators an additional (estimated) uncertainty of
around 2-5% should be added in quadrature due to the
uncertainty in finding the correct clinical axis and due
to the asymmetric and deformed dose distributions of
these applicators. For machines with high doses per
pulse an additional uncertainty of 0.5-3% (taken as the
variation of the recombination corrections for different
ionization chambers) in the correction of recombination
losses must be added, depending on pulse dose and
method of correction. The total dosimetric uncertainty
in reference dosimetry can therefore be estimated to be
2.2%-3.7% for straight and 2.9%-6.2% for beveled
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around 2% [81] for stable and between 3.5% [106] and
9.9% [86] (standard deviation of entrance dose measure-
ments) for some instable IORT accelerators. In Additional
file 2, the uncertainty due to unstable output is not in-
cluded in the calculation of the total deviation because it
is part of the dose deviations found in in-vivo dosimetry
(IVD). The standard deviations of the IVD measurements
are also taken as measure for the uncertainty caused by
set-up errors such as incorrect assessment of target
size, incomplete coverage of the target due to applica-
tor misalignment or incorrect beam entrance angle.
These uncertainties are usually not present in treat-
ments of targets of only a few millimeters thickness,
however gaps or liquid collection under the applicator
can also occur here. Neglecting the need for a 1-2cm
larger applicator diameter in breast treatments can
lead to target underdoses of 50% and more. This effect is
not considered in the calculation of the total deviation
since it can easily be avoided. The components of “uncer-
tainty” named above are added in quadrature to arrive at a
total probable deviation (Devtotal) of the applied from the
intended dose between 4.1% and 11.7%. Since most
components are taken as one standard deviation of the
applying dose variations, one can estimate that the
applied dose will lie in an interval of ± (Devtotal) around
the intended dose with a probability of 68%.
A larger spread of dose deviation is caused by the fact
that the treatment dose is prescribed to the 90% value of
the inhomogeneous dose distribution produced by the
electron beam. This leads to a intentionally planned dose
variation in the target between 100% and 111% of the
prescription value. This shall be called the variation of
intended dose. It is this range of intended IORT dose
which e.g. can be compared to the doses or the dose-
effects of other methods. Since IORT with electrons
places the prescription dose at the lower end of the
range, one can expect that dose-effects will probably be
larger than those assigned to the prescription dose. When
considering uncertainties, the total deviations Devtotal will
add linearly to the intended dose.
kV-IORT systems
The uncertainties reported for the calibrations of kV
IORT systems by different investigators range between
5.3% [90] and 10.8% [17–19]. Leaving aside the unex-
plained uncertainties in the Intrabeam calibration but
considering the differences of 4.8-8.8% between depth
dose curves measured by the manufacturer and inde-
pendently, one may estimate the uncertainty of dose
delivery by X-ray systems of the Intrabeam and Papillon
type to be around 10%. Output stability for the Intra-
beam is continuously measured during treatment, so
that it should hardly contribute to uncertainty. In acomparison of four PRS sources, Armoogum et al. [18]
report a reproducibility of the internal radiation moni-
tor within 0.23% with differences of the mean dose at
differences angles within 0.49%. Uncertainties in the
set-up can occur by missing adherence of the tissue to
the applicator surface. For a 40mm diameter applicator,
an air gap of 1mm between the applicator surface and
the tissue reduces the dose to the underlying tissues by
9% (calculated with the inverse square law). If the gap is
filled with liquid, the additional absorption will increase
the dose reduction to 14% (as read from the Zeiss depth
dose curves). For a 2mm gap the dose reductions will
be 17% for air and 26% for a liquid-filled gap. The un-
certainties in calibration and dose distribution add to a
total uncertainty of 7.2-13.4%. If gaps between applica-
tor and target tissue occur, the total deviations can rise
to between10.5%-15% and 20.1%-28.2%.
Due to the short distance the source and the strong
absorption of low energy X-rays in tissue, the dose vari-
ation in the target is very large: in a 10mm shell of target
tissue dose decreases to 34% of surface dose for a 5cm
applicator and to25% for a 3.5cm applicator. At 20 mm
distance from the surface, the dose has dropped to
15% (5cm applicator) or 10% (3.5cm applicator). The
remaining total dose deviations will add to the levels of
intended dose given by these variations. To compare the
variation of intended dose for breast treatments with kV
X-ray systems one must acknowledge that the prescription
dose at the applicator surface is about twice the dose pre-
scribed in electron treatments. This implies that means
that, for breast IORT, a dose distribution of between 111%
and 100% of prescription dose with an uncertainty of
around ±12% with electrons would compare to a dose dis-
tribution between 200% and 66-75% (for 10mm target
thickness or 20%-30% for 20mm) with an uncertainty be-
tween 10.5% and 28.2% using kV X-rays. Radiobiological
models by Herskind et al. [137–139] attempt to explain
why the kV dose distributions may give comparable treat-
ment results to electrons, however a proof of equivalence
can only be given by the final results of the Targit [22–24]
and possibly additional trials.
In summary, while the uncertainties in the dosimetry of
IORT are similar to those in external beam therapy (when
the issues in the Intrabeam calibration are clarified), the
possible unexpected deviations from intended dose due to
set-up uncertainties such as incorrect assessment of target
dimensions, gaps, blood pooling, etc. reported for IORT
are around 4-12% for electrons and 10%-28% for kV X-
rays. The set-up imponderabilia are measured by in-vivo
dosimetry as 5-10% with frequent larger outliers up to
30%. The in-vivo measurements include the possible
deviations in calibration and output stability. This
group of dose deviations can possibly be reduced by
physical improvements in dosimetry. The uncertainties
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reduced by on-line imaging and treatment planning and
therefore give reason for further development of appropri-
ate tools.
For breast treatments, the uncertainties add on to devia-
tions from intended prescription dose of 11% for electrons
and 25-34% (or70-80%) for kV X-rays inherent to the dose
gradients of the radiation, making the dose-effect relations
and outcomes of these treatments difficult to predict or
compare. This uncertainty gives need to prove the efficacy
of IORT in clinical trials, however is probably outweighed
by the obvious advantages of increasing dose while redu-
cing of dose to neighboring healthy tissues, reduction of
geographical miss, early application of treatment before
further growth of remaining tumor cells can occur, and
possible biological advantages of irradiation with single
high doses.
Conclusions
Although IORT in its present form has been used since
over 40 years, some basic requirements to ensure quality
and reproducibility of treatment remain in need of fur-
ther development. Issues found in this review include
better definition and documentation of IORT targets as
well as the need to further develop treatment planning
and reporting. Other uncertainties and surgical limita-
tions in the application such as bleeding may be more
difficult to exclude.
The possibilities to reduce the uncertainties in the cali-
bration and dosimetry of treatment with kV X-rays should
further investigated. In total one may assume a typical
uncertainty of ±10-15% for IORT procedures. To assess
the dose response of IORT one must additionally consider
the dose inhomogeneity inherent to the different tech-
nologies. Probably the present level of uncertainty is ac-
ceptable if one considers the potential benefits of IORT
for the patient. However, effort should be taken to reduce
uncertainty and the present uncertainty must be consid-
ered if one approaches tolerance doses.
IORT can help improve radiation therapy by sterilizing
cells remaining in the tumor bed after surgical resection
(“reducing surgical margins”), by allowing an advanced
boost before further tumor growth, by avoiding geograph-
ical miss and in general by escalating the dose to the
tumor. A further advantage which is difficult to measure
is the mutual education of the involved disciplines in judg-
ing the situation after tumor resection and the possibilities
of adapting radiotherapy to it. These potential benefits
from IORT have been difficult to prove, since randomized
trials are scarce. However pooled analysis has shown
improvements by IORT, as demonstrated in the reviews in
this journal. Uncertainties in dose, dose distribution and
dose-effect-relation, in documentation of the treatment
and the exact treatment site add to the difficulty inproving evidence of therapeutic benefit. The reduction
of these uncertainties may help improve the quality of
IORT, and help provide better data to prove evidence
of the therapeutic benefit of IORT.Additional files
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